Fasenra granted US Orphan Drug Designation for eosinophilic oesophagitis
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of eosinophilic oesophagitis…
Read More...
Read More...
